{"product_id":"gh-swot-analysis","title":"(GH) Guardant Health, Inc. SWOT Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValidate Every Claim with the Complete Sources File\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Guardant Health, Inc. SWOT Analysis gives a concise, structured view of the company’s strengths, weaknesses, opportunities, and threats to support research, strategy, or investment decisions; the content shown on this page is a genuine preview of the actual analysis, not just marketing copy. Purchase the full version to download the complete, ready-to-use report and save research time.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStrengths\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuardant360 LDT and CDx\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardant360 is Guardant Health, Inc.'s flagship liquid biopsy, sold as both LDT and FDA-approved CDx, which strengthens its reach in advanced-stage cancer testing. The CDx label supports therapy selection and payer trust, while the LDT format broadens clinical use. In 2025, Guardant Health reported revenue growth driven by oncology testing, underscoring Guardant360's core role.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti-product oncology portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardant Health, Inc. sells five oncology offerings: Guardant360, GuardantOMNI, Guardant Reveal, tissue genotyping, and Guardant-19. That breadth reduces dependence on any one assay and lets the Company serve early-, advanced-, and recurrence-monitoring use cases. It also widens reach across physicians, hospitals, and biopharma partners.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge clinical-genomic dataset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardantINFORM sits on a large clinical-genomic liquid biopsy dataset from advanced cancer patients, giving Guardant Health a data moat that keeps improving with each new test. That scale can sharpen analytics, speed R\u0026amp;D, and improve product design, while smaller rivals would need years and many thousands of cases to catch up. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEarly detection pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGuardant Health, Inc.’s early detection pipeline is a real strength because LUNAR-2 is aimed at asymptomatic colorectal cancer screening, moving the company beyond late-stage oncology and into a far larger prevention market. U.S. guidance already supports routine CRC screening starting at age 45, which opens access to tens of millions of eligible adults.\u003c\/p\u003e\n\u003cp\u003eIf LUNAR-2 shows strong clinical performance, it could widen Guardant Health, Inc.’s addressable market well beyond treatment monitoring and recurrence tests. That matters in a sector where the company already posted 2025 revenue above $700 million, so a successful screening product could become a major second growth engine.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets asymptomatic CRC screening\u003c\/li\u003e\n\u003cli\u003eExpands beyond late-stage oncology\u003c\/li\u003e\n\u003cli\u003eReaches a much larger market\u003c\/li\u003e\n\u003cli\u003eCould add a future growth engine\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiopharma and institutional services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGuardant Health, Inc. uses biopharma and institutional services to go beyond test sales by offering companion diagnostic development, regulatory support, clinical study management, and kit fulfillment. That makes the business stickier because partners often build these services into drug programs and keep them through launch.\u003c\/p\u003e\n\u003cp\u003eThese services also add revenue streams that can scale with more pharma deals and clinical trials, not just patient testing demand. One line: once a partner is embedded, switching is costly and slow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDeepens biopharma and lab ties\u003c\/li\u003e\n\u003cli\u003eAdds non-test revenue streams\u003c\/li\u003e\n\u003cli\u003eRaises partner switching costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuardant’s Broad Oncology Franchise and Early-Detection Upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuardant Health, Inc.’s main strength is Guardant360, a liquid biopsy sold as both LDT and FDA-approved CDx, which supports broad use in advanced cancer care. Its five-product oncology menu lowers single-assay risk, while GuardantINFORM creates a growing clinical-genomic data moat. The early-detection push with LUNAR-2 could open a much larger screening market. 2025 revenue topped $700 million.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003cth\u003eStrength signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e$700M+\u003c\/td\u003e\n\u003ctd\u003eRevenue scale and portfolio breadth\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear SWOT framework for analyzing Guardant Health, Inc.’s business strategy\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eDelivers a quick, structured SWOT snapshot for Guardant Health, Inc. to simplify strategy review and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eConsolidates primary industry reports, peer-reviewed studies, company filings, and government datasets to fast-track verification and reduce uncertainty in Guardant Health analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eWeaknesses\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy focus on cancer diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardant Health, Inc. is heavily tied to precision oncology, so its results hinge on how fast cancer screening and treatment testing keep gaining traction. That is a narrow base: if oncology demand slows, both liquid biopsy and related testing revenue can weaken at the same time. With cancer diagnostics still the core of the business, any shift in adoption, reimbursement, or clinician use hits Guardant Health, Inc. across the board.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePipeline still in development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardant Health, Inc.’s pipeline is still early, so LUNAR-2 and GuardantConnect have not yet turned into steady recurring revenue. In 2024, the Company reported about $742 million in revenue, but future upside still depends on clinical, regulatory, and commercial progress. Any delay could push out growth and pressure expectations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardant Health, Inc. still depends heavily on payer coverage for blood-based cancer tests, even after 2024 revenue rose to about $739 million. When reimbursement is slow or narrow, test volume can lag clinical demand, so adoption may move slower than the science. That can squeeze margins too, since pricing pressure and collection delays hit a business that is still not consistently profitable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eComplex product mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGuardant Health, Inc. runs four different businesses across diagnostics, analytics, research software, and development services, so sales and support are not built on one simple model. That mix can slow execution because each line needs its own go-to-market path, reimbursement work, and regulatory tracking. In 2024, revenue was $675.2 million, and managing that spread across multiple product types can still pressure efficiency.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFour business models raise complexity.\u003c\/li\u003e\n\u003cli\u003eSales and support need split focus.\u003c\/li\u003e\n\u003cli\u003eRegulatory paths are not the same.\u003c\/li\u003e\n\u003cli\u003eEfficiency can slip across units.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInternational expansion friction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGuardant Health sells in the U.S. and abroad, but cross-border diagnostics face country-by-country regulatory reviews, reimbursement gaps, and market-access delays. That can slow uptake outside the core U.S. base, where the company still gets most of its revenue. In 2024, Guardant Health reported $686.7 million in revenue, underscoring how scaling overseas remains a real drag.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCountry rules slow launches\u003c\/li\u003e\n\u003cli\u003ePayer coverage is uneven\u003c\/li\u003e\n\u003cli\u003eU.S. revenue still dominates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuardant Health’s Growth Hinges on Reimbursement and Oncology Adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuardant Health, Inc. remains exposed to a narrow cancer-testing mix, so slower oncology adoption can hit revenue fast. Reimbursement is still a key weak spot, and uneven payer coverage can delay volume growth and pressure margins. Complex multi-unit operations also raise execution risk. In 2024, revenue was about $739 million, but profitability stayed under pressure.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eWeakness\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eReimbursement risk\u003c\/td\u003e\n\u003ctd\u003e2024 revenue about $739M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNarrow oncology mix\u003c\/td\u003e\n\u003ctd\u003eCore business concentration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExecution complexity\u003c\/td\u003e\n\u003ctd\u003eMultiple business lines\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eGuardant Health, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get; purchasing unlocks the complete, editable version with in-depth strengths, weaknesses, opportunities, and threats for Guardant Health, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eOpportunities\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLUNAR-2 colorectal screening\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLUNAR-2 targets early colorectal cancer detection in asymptomatic people, which opens a far larger market than late-stage testing. In the U.S., screening starts at age 45, covering roughly 100 million adults. If LUNAR-2 gains adoption, it could expand Guardant Health, Inc.’s addressable market well beyond the metastatic setting and support higher long-term recurring revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuardantConnect clinical trial matching\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardantConnect can turn Guardant360 results with actionable alterations into trial matches, which adds value beyond diagnosis. ClinicalTrials.gov lists 500,000+ studies, so the pool for matching is large. That can make Guardant Health more useful to physicians and help deepen biopharma ties, since each matched patient can support drug development and may lift the value of every test result.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion in companion diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardant Health, Inc. already sells companion diagnostic development and regulatory support, and its Guardant360 CDx has FDA approval for 20+ therapy labels, which gives it a strong base for more drug-test co-development. In FY2024, revenue was about $708 million, so even small biopharma wins can add meaningful repeat work. More pairing deals can deepen pharma ties and create recurring development revenue alongside routine clinical testing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGrowth in early-stage cancer testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGuardant Reveal gives Guardant Health a foothold in early-stage cancer care by helping guide treatment after surgery, especially in colorectal cancer. Early-stage disease is the bigger testing pool: about 1.9 million new cancer cases were expected in the U.S. in 2025, and most are still found before metastatic spread. Wider use of Reveal could reduce reliance on advanced-stage oncology and broaden revenue. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets a much larger patient pool\u003c\/li\u003e\n\u003cli\u003eSupports treatment selection after surgery\u003c\/li\u003e\n\u003cli\u003eCan diversify revenue mix\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eData monetization and analytics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGuardant Health, Inc.'s GuardantINFORM can turn its large clinical-genomic dataset into higher-value analytics, research partnerships, and evidence generation. That shifts revenue mix toward data services, which can carry better margins than pure test volume. This also deepens the moat around the liquid biopsy platform by making each test more valuable over time.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore data, better margins\u003c\/li\u003e\n\u003cli\u003eSupports research deals\u003c\/li\u003e\n\u003cli\u003eStrengthens evidence sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLUNAR-2 Opens a 100M-Patient Screening Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLUNAR-2 can open a much larger early-screening market, since U.S. colorectal screening starts at 45 and covers about 100 million adults. GuardantConnect and GuardantINFORM can lift value per test through trial matching and data sales. Guardant360 CDx also has 20+ FDA-linked therapy labels, which supports more pharma work.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eOpportunity\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLUNAR-2\u003c\/td\u003e\n\u003ctd\u003e100M U.S. screening pool\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGuardant360 CDx\u003c\/td\u003e\n\u003ctd\u003e20+ therapy labels\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGuardantConnect\u003c\/td\u003e\n\u003ctd\u003e500,000+ trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eThreats\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompetitive liquid biopsy market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLiquid biopsy is a crowded diagnostics field, and larger peers like Illumina and Exact Sciences can use bigger sales networks, lower pricing, and wider assay menus to win accounts. Guardant Health, Inc. already faced this pressure in 2024, when revenue was $713.9 million, so any share gain still has to fight heavy competition. That can slow adoption and keep gross margin under strain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory approval risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardant Health, Inc. faces real approval risk because key products still depend on FDA and payer milestones; any delay can push back revenue and shake investor confidence. That matters most for LUNAR-2, where commercialization hinges on clean clinical and regulatory progress after Guardant Health, Inc. posted 2024 revenue of about $716 million, so even a slip can hit a fast-growing base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eReimbursement pressure is a key threat for Guardant Health, Inc. because oncology diagnostics face close payer review on clinical utility and cost. Coverage can shift by payer and market, and weaker coverage can quickly cut test volumes and average selling prices. For a company that reported 2025 revenue growth tied to its oncology and screening tests, even small cuts in reimbursement can hit operating leverage fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical validation risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical validation risk is high for Guardant Health, Inc. because screening and treatment-selection tests must prove clear clinical benefit before doctors adopt them. In 2024, Guardant Health reported $716.9 million in revenue, but early detection products like Shield still depend on stronger real-world data to scale. If studies do not show better outcomes or clear decision value, uptake can stay limited, which slows reimbursement and revenue growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEvidence drives physician adoption.\u003c\/li\u003e\n\u003cli\u003eWeak data limits screening use.\u003c\/li\u003e\n\u003cli\u003eEarly detection faces the most risk.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eExecution risk across multiple launches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGuardant Health, Inc. faces execution risk because it is pushing at least 2 major initiatives at once, including LUNAR-2 and GuardantConnect. That raises strain on sales, manufacturing, and field support, and any slip in rollout can slow revenue capture even if the science is strong.\u003c\/p\u003e\n\u003cp\u003eThe risk is not the product idea; it is the timing and scale of execution. If launch cadence, reimbursement, or customer onboarding lag in 2025-2026, growth can miss internal targets and dilute operating leverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2 launches increase execution load.\u003c\/li\u003e\n\u003cli\u003eSales capacity can get stretched.\u003c\/li\u003e\n\u003cli\u003eOperational misses can delay growth.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuardant Health’s Growth Faces Fierce Competition and Reimbursement Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuardant Health, Inc. faces sharp competition in liquid biopsy, where bigger rivals can undercut pricing and win accounts faster, pressuring margins on its 2024 revenue base of $716.9 million. Reimbursement and FDA timing are the bigger swing factors: delays on LUNAR-2 or weaker payer coverage can quickly cut volume. \u003c\/p\u003e\n\u003cp\u003eClinical proof still drives adoption, so weak screening data can slow Shield and keep growth uneven. With at least 2 major launches running at once, execution risk is high and any rollout miss can delay revenue capture. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eThreat\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetition\u003c\/td\u003e\n\u003ctd\u003eLarge peers, 2024 revenue $716.9 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory and payer risk\u003c\/td\u003e\n\u003ctd\u003eLUNAR-2 and reimbursement remain gatekeepers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExecution risk\u003c\/td\u003e\n\u003ctd\u003eAt least 2 major initiatives in flight\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234414338313,"sku":"gh-swot-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/gh-swot-analysis.webp?v=1785719841","url":"https:\/\/dcfanalyst.com\/products\/gh-swot-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}